Prosecution Insights
Last updated: April 19, 2026
Application No. 17/775,986

SOIL WETTER COMPOSITION

Non-Final OA §103
Filed
May 11, 2022
Examiner
HOLT, ANDRIAE M
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Croda International PLC
OA Round
3 (Non-Final)
48%
Grant Probability
Moderate
3-4
OA Rounds
3y 11m
To Grant
70%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allow Rate
354 granted / 731 resolved
-11.6% vs TC avg
Strong +21% interview lift
Without
With
+21.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
54 currently pending
Career history
785
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
48.5%
+8.5% vs TC avg
§102
15.9%
-24.1% vs TC avg
§112
20.4%
-19.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 731 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on January 2, 2026 has been entered. Claims 1-13 and 15-17 are pending in the application. Claims 10-12 are withdrawn as being drawn to a nonelected invention. Claims 1, 2, 8, and 13 have been amended. Claims 1-9, 13, and 15-17 will presently be examined to the extent they read on the elected subject matter of record. Status of the Claims The rejection of claims 1-9, 13, and 15-16 under 35 U.S.C. 103 as being unpatentable over Blease et al. (WO 2014/181099) in view of Lindner et al. (WO 2012/024276) is maintained. The rejection of claim 17 under 35 U.S.C. 103 as being unpatentable over Blease et al. (WO 2014/181099) in view of Lindner et al. (WO 2012/024276) as applied to claims 1-9 and 13-17 above, and further in view of the Stepan Alkoxylate Product Guide (2020, Stepan Alkoxylates) is maintained. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-9, 13, and 15-16 are rejected under 35 U.S.C. 103 as being unpatentable over Blease et al. (WO 2014/181099) in view of Lindner et al. (WO 2012/024276). Blease et al. and Lindner et al. cited by Applicant on the IDS dated 5/11/2022. Applicant’s Invention Applicant claims a soil treatment formulation consisting of: (i) ethoxylated/propoxylated fatty acid mono-esters of sorbitan wherein the carbon chain length of the fatty acid is from 8 to 16, and the overall degree of ethoxylation is on average from 5 to 25; (ii) ethylene oxide-propylene oxide copolymer, and (iii) compatibilising surfactant selected from an alkoxylated fatty alcohol, alkoxylated fatty alcohol phosphate ester, and/or alkoxylated glycerides and (iv) one or more of a biocide, a nutrient, a binder, a starch, a diluent, an absorbent, a surfactant, a swelling agent, a wetting agent, a dispersant, an emulsifier, an antifoam agent, a viscosity modifier and preservative. Determination of the scope of the content of the prior art (MPEP 2141.01) Regarding claim 1, Blease et al. teach a method and/or conditioning soil comprises applying a soil treatment composition containing hydrolysed protein to the soil. The soil treatment composition contains a surfactant selected from ethylene oxide-propylene oxide (EO/PO) block copolymer and/or an alkyl polyglycoside (Abstract, page 15, claim 3). Blease et al. teach the soil treatment composition comprises (i) hydrolysed protein, (ii) at least on polyalkylene oxide block copolymer(s), and (iii) at least one additional surfactant selected from fatty acid alkoxylates, fatty alcohol alkoxylates and alkoxylated glyceride esters (page 8, lines 32-34-page 9, lines 1-2). Regarding claim 1, Blease et al. teach that examples of suitable protein include wheat starch (page 3, lines 1-2). Blease et al. teach the hydrolysed protein component may contain starch, for example hydrolysed wheat protein may contain wheat starch (page 3, lines 9-11). The hydrolysed protein that is wheat starch reads on component (iv) a starch. Regarding claim 3, Blease et al. teach the polyalkylene oxide block copolymers have an average molecular weight of 1,500 to 15,000 (page 5, lines 8-10). Regarding claims 4, 5, and 6, Blease et al. teach the suitable hydrophobized alkoxylate surfactant include alcohol alkoxylates of the formula (a) R1-O-(AO)n-H, wherein R1 is C8 to C24, AO is independently ethylene oxide or propylene oxide group and n in the molecule is from 2 to 200 (page 7, lines 13-20). Regarding claim 7, Blease et al. teach test solutions were prepared in water to give solutions containing 14.5% active solids (page 13, lines 1-4). Regarding claim 8, Blease et al. teach the soil treatment concentrate is formed which will generally be diluted prior to applying to the soil (page 4, lines 6-8). Regarding claim 9, Blease et al. teach a method and/or conditioning soil comprising applying a soil treatment composition (page 15, claim 1). Regarding claim 16, Blease et al. teach the ethylene oxide-propylene oxide (EO/PO) block polymer has an average molecular weight of approx. 2400, which falls within the range of 1,200 to 8,000 currently claimed (page 5, lines 21-22). Blease et al. teach the soil treatment composition may further comprise at least one additional surfactant, i.e. not a polyalkylene oxide block copolymer or alkyl polyglycoside (page 6, lines 12-15). Ascertainment of the difference between the prior art and the claims (MPEP 2141.02) Blease et al. do not specifically disclose the composition comprises ethoxylated/propoxylated fatty acid mono-esters of sorbitan wherein the carbon chain length of the fatty acid is from 8 to 16, and the overall degree of ethoxylation is on average from to 35. It is for this reason Lindner et al. is added as a secondary reference. Lindner et al. teach ethoxylated fatty acid mono-ester(s) of sorbitan with a fatty acid chain length from 8 to 14 and an overall degree of ethoxylation from 7 to 16 (Abstract). Regarding claim 2, Lindner et al. teach the ethoxylated fatty acid mono-esters of sorbitan are compounds of formula (I): PNG media_image1.png 195 480 media_image1.png Greyscale (page 15, claim 10). Lindner et al. teach it is found that the solution behaviour and wetting properties of mono-esters are superior in agrochemical adjuvant applications (page 4, paragraph [0024]). Lindner et al. teach the agrochemical include additional ingredients such as surfactants (page 7, paragraph [0044]). Regarding claim 13, Lindner et al. teach the sorbitan residue is formed from 1,4-androsobitol, 1,5-anhydrosorbitol, and 3,6-anhydrosorbitol (page 14, claim 4). Regarding claim 14, Lindner et al. teach the mixture may also typically include some 1,4,3,6-dianhydrosorbitol (page 3, paragraph [0021]. Regarding claim 15, Lindner et al. teach the carbon chain length of the fatty acid is from 10-4 (page 14, claim 6). Finding of prima facie obviousness Rationale and Motivation (MPEP 2142-2143) It would have been obvious to one of ordinary skill in the art before the effective filing date of the invention to combine the teachings of Blease et al. and Lindner et al. and use ethoxylated/propoxylated fatty acid mono-esters of sorbitan wherein the carbon chain length of the fatty acid is from 8 to 16, and the overall degree of ethoxylation is on average from 5 to 25. Blease et al. teach a soil treatment composition comprises (i) hydrolysed protein, (ii) at least on polyalkylene oxide block copolymer(s), and (iii) at least one additional surfactant selected from fatty acid alkoxylates, fatty alcohol alkoxylates and alkoxylated glyceride esters. Blease et al. teach suitable hydrolysed protein include wheat starch. Blease et al. teach a method and/or conditioning soil comprising applying a soil treatment composition. Blease et al. teach the soil treatment composition may further comprise at least one additional surfactant, i.e. not a polyalkylene oxide block copolymer or alkyl polyglycoside (page 6, lines 12-15). One of ordinary skill in the art would have been motivated to add an ethoxylated fatty acid mono-ester of sorbitan of formula (I) PNG media_image1.png 195 480 media_image1.png Greyscale to the soil treatment formulations taught by Blease et al. Since Lindner et al. teach the mono-ester of sorbitan of formula (I) is used in agrochemical formulations to treat soil around crops that reduce antagonism between active combinations, one of ordinary skill in the art would have been motivated to use the sorbitan of mono-ester of sorbitan of formula (I) with a reasonable expectation of success, as a person with ordinary skill has good reason to pursue known options within his or technical grasp. Note: MPEP 2141 [R-6] KSR International CO. v. Teleflex lnc. 82 USPQ 2d 1385 (Supreme Court 2007). Therefore, the claimed invention as a whole would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made. Claim 17 is rejected under 35 U.S.C. 103 as being unpatentable over Blease et al. (WO 2014/181099) in view of Lindner et al. (WO 2012/024276) as applied to claims 1-9 and 13-17 above, and further in view of the Stepan Alkoxylate Product Guide (2020, Stepan Alkoxylates). Applicant’s Invention Applicant claims a soil treatment formulation comprising: (i) ethoxylated/propoxylated fatty acid mono-esters of sorbitan wherein the carbon chain length of the fatty acid is from 8 to 16, and the overall degree of ethoxylation is on average from 5 to 25; (ii) ethylene oxide-propylene oxide copolymer, and (iii) compatibilising surfactant selected from an alkoxylated fatty alcohol, alkoxylated fatty alcohol phosphate ester, and/or alkoxylated glycerides. Determination of the scope of the content of the prior art (MPEP 2141.01) The teachings of Blease et al. and Lindner et al. with respect to the 35 U.S.C. 103 rejection is hereby incorporated and are therefore applied in the instant rejection as discussed above. Ascertainment of the difference between the prior art and the claims (MPEP 2141.02) Blease et al. and Lindner et al. do not specifically disclose the average molecular weight of the compatibilising surfactant is 1,000 to 8,000. It is for this reason the Stepan Alkoxylate Product Guide is added as a secondary reference. The Stepan Alkoxylate Product Guide teaches various alkoxylates including BIO-SOFT® E-840 and BIO-SOFT® E-847, C12-14 Alcohol ethoxylates that has a molecular weight of 1209 (page 1, Lauryl Alcohol Ethoxylates). The Stepan Alkoxylate Product Guide teaches alcohol alkoxylates, including MAKON® TD-50 and TOXIMUL® 8315, which have molecular weights of 2478 and 3500, respectively. The molecular weights for the Alcohol Alkoxylates range from 2478-6200(page 4, Alcohol Alkoxylates). Finding of prima facie obviousness Rationale and Motivation (MPEP 2142-2143) It would have been obvious to one of ordinary skill in the art before the effective filing date of the invention to combine the teachings of Blease et al., Lindner et al., and the Stepan Alkoxylate Product Guide and use a compatibilising surfactant with an average molecular weight of 1,000 to 8,000. Blease et al. teach a soil treatment composition comprises (i) hydrolysed protein, (ii) at least on polyalkylene oxide block copolymer(s), and (iii) at least one additional surfactant selected from fatty acid alkoxylates, fatty alcohol alkoxylates and alkoxylated glyceride esters. Blease et al. teach the suitable hydrophobized alkoxylate surfactant include alcohol alkoxylates of the formula (a) R1-O-(AO)n-H, wherein R1 is C8 to C24, AO is independently ethylene oxide or propylene oxide group and n in the molecule is from 2 to 200. The Stepan Alkoxylate Product Guide teaches various alkoxylates including lauryl alcohol ethoxylates and alcohol alkoxylates that fall within the definition of compatibilising surfactants claimed and the alcohol alkoxylates taught by Blease et al. The Alkoxylate Product Guide teaches the molecular weights range from 1209 to 6200. As such, it would have been obvious to one of ordinary skill in the art that the compatibilising surfactants taught by Blease et al., as modified by Lindner et al., would have average molecular weights in the range of 1,000 to 8,000, without evidence to the contrary. Therefore, the claimed invention as a whole would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made. Response to Arguments Applicant's arguments filed January 2, 2026 have been fully considered but they are not persuasive. Applicant argues that claim 1 has been amended to replace “comprising” with “consisting of” as it relates to the soil treatment formulation. Applicant argues that as amended, the soil treatment formulation of claim 1 does not contain a hydrolyzed protein as required by Blease and that Lindner is unable to cure this deficiency in Blease. In response to Applicant’s argument, independent claim 1 has also been amended to add the limitation of component (iv) one or more of a biocide, a nutrient, a binder, a sugar, a starch…and a preservative. Blease et al. teach that examples of suitable protein include wheat starch. Blease et al. further teach the hydrolysed protein component may contain starch, for example hydrolysed wheat protein may contain wheat starch. As such, since Blease et al. teach the hydrolysed protein can be wheat starch, it would have been obvious to one of ordinary skill in the art that the hydrolysed protein that is wheat starch reads on a starch as component (iv), without evidence to the contrary. The claims remained rejected. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Andriae M Holt whose telephone number is (571)272-9328. The examiner can normally be reached Monday-Friday, 8:00 am-4:30 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANDRIAE M HOLT/Examiner, Art Unit 1614 /ALI SOROUSH/Supervisory Patent Examiner, Art Unit 1614
Read full office action

Prosecution Timeline

May 11, 2022
Application Filed
May 15, 2025
Non-Final Rejection — §103
Aug 08, 2025
Response Filed
Nov 13, 2025
Final Rejection — §103
Jan 02, 2026
Response after Non-Final Action
Jan 20, 2026
Request for Continued Examination
Jan 23, 2026
Response after Non-Final Action
Mar 17, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12588677
Herbicidal compositions comprising topramezone
2y 5m to grant Granted Mar 31, 2026
Patent 12582132
GERMINATION/SPROUTING AND FRUIT RIPENING REGULATORS
2y 5m to grant Granted Mar 24, 2026
Patent 12583826
[(1,5-DIPHENYL-1H-1,2,4-TRIAZOL-3-YL)OXY]ACETIC ACID DERIVATIVES AND SALTS THEREOF, CROP PROTECTION COMPOSITIONS COMPRISING THEM, METHODS FOR PRODUCING THEM AND USE THEREOF AS SAFENERS
2y 5m to grant Granted Mar 24, 2026
Patent 12582122
Herbicidal compositions comprising clethodim
2y 5m to grant Granted Mar 24, 2026
Patent 12570657
MESYLATE SALTS OF HETEROCYCLIC CYTOKININS, COMPOSITIONS CONTAINING THESE DERIVATIVES AND USE THEREOF
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
48%
Grant Probability
70%
With Interview (+21.2%)
3y 11m
Median Time to Grant
High
PTA Risk
Based on 731 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month